Skip to main navigation
Skip to search
Skip to main content
Universidad de los Andes Home
English
Español
Search content at Universidad de los Andes
Home
Profiles
Research units
Research output
Projects
Press/Media
Activities
Equipment
Student theses
Prizes
Courses
Impacts
Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder
Manuel Gardea-Resendez
, Monica J. Taylor-Desir
, Francisco Romo-Nava
, David Bond
, Eric J. Vallender
, Alfredo B. Cuellar-Barboza
,
Miguel L. Prieto
, Nicolas Nunez
, Marin Veldic
, Aysegul Ozerdem
, Balwinder Singh
, Matej Markota
, Colin L. Colby
, Brandon J. Coombes
, Joanna M. Biernacka
, Susan L. McElroy
, Mark A. Frye
*
*
Corresponding author for this work
Clínica Universidad de los Andes
Programa de Neurociencias
Departamento de Psiquiatría
Medicina
Facultad de Medicina
Universidad de los Andes
Centro de Investigación e Innovación Biomédica
Research output
:
Contribution to journal
›
Article
›
peer-review
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Clinical Phenotype
100%
Bipolar Disorder
100%
Tardive Dyskinesia
100%
Antipsychotics
50%
Tardive
33%
Cumulative Exposure
33%
Usage Patterns
33%
Antipsychotic Use
33%
Clinical Variables
16%
Risk Factors
16%
Prevalence Rate
16%
Treatment Outcome
16%
T-test
16%
Case-based Analysis
16%
Negative Impact
16%
Number of Trials
16%
Disease Severity
16%
Movement Disorders
16%
Clinical Correlation
16%
Mean Dose
16%
Bipolar Subtypes
16%
Atypical Antipsychotics
16%
Severity Assessment
16%
Individualized Care
16%
Haloperidol
16%
Stabilization Treatment
16%
Treatment Quality
16%
Induced Motion
16%
Second-generation Antipsychotics
16%
Quality of Life Outcomes
16%
Mood Stabilization
16%
Pharmacology, Toxicology and Pharmaceutical Science
Bipolar Disorder
100%
Tardive Dyskinesia
100%
Antipsychotic
50%
Typical Antipsychotic
50%
Prevalence
16%
Cross-Sectional Study
16%
Biological Marker
16%
Motor Dysfunction
16%
Disease Severity
16%
Atypical Antipsychotics
16%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
16%
Neuroscience
Bipolar Disorder
100%
Tardive Dyskinesia
100%
Typical Antipsychotic
50%
Antipsychotic
50%
Stereotypic Movement Disorder
16%
Atypical Antipsychotic
16%
Haloperidol
16%
Psychology
Bipolar Disorder
100%
Tardive Dyskinesia
100%
Mood
20%
Quality of Life
20%
Movement Disorder
20%
Haloperidol
20%